Sep 30, 2023

Alkermes Q3 2023 Earnings Report

Alkermes reported solid financial results for Q3 2023, driven by revenue growth and strategic capital allocation.

Key Takeaways

Alkermes reported Q3 2023 financial results with total revenues of $380.9 million and GAAP net income of $47.8 million. Net sales of proprietary products increased approximately 16% year-over-year. The company reiterated its financial expectations for full-year 2023 and expects to complete the separation of its oncology business in November 2023.

Total revenues for the quarter were $380.9 million.

Net sales of proprietary products increased approximately 16% year-over-year to $231.8 million.

GAAP net income was $47.8 million, or $0.28 per diluted share.

The company expects to complete the separation of its oncology business in November 2023.

Total Revenue
$381M
Previous year: $252M
+51.0%
EPS
$0.64
Previous year: $0.02
+3100.0%
Gross Profit
$319M
Previous year: $101M
+215.3%
Cash and Equivalents
$996M
Previous year: $747M
+33.3%
Free Cash Flow
$85.3M
Previous year: -$9.85M
-965.6%
Total Assets
$2.28B
Previous year: $1.94B
+17.4%

Alkermes

Alkermes

Alkermes Revenue by Segment

Forward Guidance

Alkermes reiterated its financial expectations for full-year 2023, as set forth in its press release dated June 6, 2023.

Revenue & Expenses

Visualization of income flow from segment revenue to net income